ArticleJournal of global oncology2017
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer.
Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.Frontiers in pharmacology · 2025Pooled it
- A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.Pathology oncology research : POR · 2019Pooled it
- A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.Cancer research and treatment · 2021Trial
- Association of Expression of YTH-Domain Family Protein 3 (YTHDF3) With Brain Metastases and Unfavorable Survival in Patients With Stage IV Lung Adenocarcinoma.Molecular carcinogenesis · 2026Article
- The Landscape and Management of Brain Parenchymal and Leptomeningeal Metastases in EGFR Mutated Non-Small Cell Lung Cancer.Cancers · 2025Review
- Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.JTO clinical and research reports · 2025Article
- Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasis.Frontiers in oncology · 2025Article
- Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer.Exploration of targeted anti-tumor therapy · 2023Article
- Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma-An Indian Perspective of 212 Patients.International journal of environmental research and public health · 2022Article
- Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.Journal of neuro-oncology · 2022Article
- Hippocampal Metastasis Rate Based on Non-Small Lung Cancer TNM Stage and Molecular Markers.Frontiers in oncology · 2022Article
- Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India.JCO global oncology · 2021Observational
- Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.BMC cancer · 2020Article
- Suppression of Circular RNA Hsa_circ_0109320 Attenuates Non-Small Cell Lung Cancer Progression via MiR-595/E2F7 Axis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Whole-Brain Radiotherapy Can Improve the Survival of Patients with Multiple Brain Metastases from Non-Small Cell Lung Cancer Treated by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.Cancer management and research · 2020Article
- Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis.Journal of Cancer · 2020Article
- Risk factors for brain metastases in patients with non-small-cell lung cancer.Cancer medicine · 2018Review
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.The oncologist · 2018Review
- Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases.Journal of neuro-oncology · 2018Article
- Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpidermal growth factor receptor (
methodsThis retrospective study included 1,522 consecutive patients with NSCLC, whose tumors were diagnosed and tested for
resultsEGFR mutations were more common in females than males (38.7%
conclusionThere is a nearly two-fold higher incidence of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.